Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$5,129 Mln
P/E Ratio
--
P/B Ratio
4.79
Industry P/E
--
Debt to Equity
--
ROE
-0.29 %
ROCE
-29.46 %
Div. Yield
0 %
Book Value
16.21
EPS
-3.95
CFO
$-229.30 Mln
EBITDA
$-299.58 Mln
Net Profit
$-272.27 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Nuvalent Inc (NUVL)
| -8.81 | -8.44 | -8.81 | 13.73 | 86.24 | -- | -- |
|
BSE Sensex
| 1.72 | 3.50 | 4.95 | 8.90 | 11.18 | 21.04 | 11.14 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
|
|---|---|---|---|
|
Nuvalent Inc (NUVL)
| 6.32 | 147.11 | 56.41 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 36.35 | 9,973.38 | 20.56 | 23.13 | |
| 283.07 | 8,956.07 | 23.48 | 58.42 | |
| 25.36 | 9,559.25 | -- | -28.77 | |
| 101.76 | 10,030.35 | 30.81 | 14.16 |
Nuvalent, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent... treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the Phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the Phase 2 portion of the ALKOVE-1 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR that is in Phase 1a/1b clinical trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts. Address: One Broadway, Cambridge, MA, United States, 02142 Read more
CEO, President & Director
Dr. James R. Porter Ph.D.
CEO, President & Director
Dr. James R. Porter Ph.D.
Headquarters
Cambridge, MA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Nuvalent Inc (NUVL) stood at $ 1,142 Mln as on 31-Dec-24
The share price of Nuvalent Inc (NUVL) is $71.38 (NASDAQ) as of 22-Apr-2025 15:41 EDT. Nuvalent Inc (NUVL) has given a return of 86.24% in the last 3 years.
Nuvalent Inc (NUVL) has a market capitalisation of $ 5,129 Mln as on 21-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Nuvalent Inc (NUVL) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Nuvalent Inc (NUVL) and enter the required number of quantities and click on buy to purchase the shares of Nuvalent Inc (NUVL).
Nuvalent, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the Phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the Phase 2 portion of the ALKOVE-1 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR that is in Phase 1a/1b clinical trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts. Address: One Broadway, Cambridge, MA, United States, 02142
The CEO & director of Dr. James R. Porter Ph.D.. is Nuvalent Inc (NUVL), and CFO & Sr. VP is Dr. James R. Porter Ph.D..
There is no promoter pledging in Nuvalent Inc (NUVL).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,012
|
|
|
990
|
|
|
974
|
|
|
896
|
| Nuvalent Inc (NUVL) | Ratios |
|---|---|
|
Return on equity(%)
|
-29.46
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
--
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Nuvalent Inc (NUVL) was $0 Mln.
$1.43
(
